Download Table of Contents - Clinical Cancer Research

Clinical Cancer Research
Table of
Contents
January 1, 2016 Volume 22 Number 1
34
Highlights of This Issue 1
SPECIAL FEATURES
CCR Translations
3
Jatin J. Shah, Andrzej J. Jakubowiak, Owen A. O0 Connor,
Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith,
Daniel Lebovic, Catherine Diefenbach, Kevin Kelly,
Zhaowei Hua, Allison J. Berger, George Mulligan,
Helene M. Faessel, Stephen Tirrell, Bruce J. Dezube, and
Sagar Lonial
Right-Sizing Adjuvant and Neoadjuvant Clinical
Trials in Breast Cancer
Donald A. Berry
See related article, p. 26
6
Is It Better to Be Rich or Relaxed? Sociobiology
Meets Bone Marrow Transplant
44
Lucie M. Turcotte and Michael R. Verneris
See related article, p. 69
New Strategies in Prostate Cancer: ProstateSpecific Membrane Antigen (PSMA) Ligands for
Diagnosis and Therapy
54
Uwe Haberkorn, Matthias Eder, Klaus Kopka,
John W. Babich, and Michael Eisenhut
Molecular Pathways: IDH2 Mutations—Co-opting
Cellular Metabolism for Malignant
Transformation
Eytan M. Stein
61
Review
20
An Open-Label, Randomized Phase II Trial of
Personalized Peptide Vaccination in Patients with
Bladder Cancer that Progressed after PlatinumBased Chemotherapy
Masanori Noguchi, Kazumasa Matsumoto,
Hirotsugu Uemura, Gaku Arai, Masatoshi Eto, Seiji Naito,
Chikara Ohyama, Yasutomo Nasu, Masatoshi Tanaka,
Fukuko Moriya, Shigetaka Suekane, Satoko Matsueda,
Nobukazu Komatsu, Tetsuro Sasada, Akira Yamada,
Tatsuyuki Kakuma, and Kyogo Itoh
Molecular Pathways
16
A Phase II Trial of the Multitargeted Tyrosine
Kinase Inhibitor Lenvatinib (E7080) in Advanced
Medullary Thyroid Cancer
Martin Schlumberger, Barbara Jarzab, Maria E. Cabanillas,
Bruce Robinson, Furio Pacini, Douglas W. Ball,
Judith McCaffrey, Kate Newbold, Roger Allison,
Renato G. Martins, Lisa F. Licitra, Manisha H. Shah,
Donald Bodenner, Rossella Elisei, Lynn Burmeister,
Yasuhiro Funahashi, Min Ren, James P. O’Brien, and
Steven I. Sherman
CCR New Strategies
9
Phase I Study of the Novel Investigational
NEDD8-Activating Enzyme Inhibitor
Pevonedistat (MLN4924) in Patients with
Relapsed/Refractory Multiple Myeloma or
Lymphoma
From DNA Damage to Nucleic Acid Sensing:
A Strategy to Enhance Radiation Therapy
A Multicenter, Open-Label Phase II Clinical Trial
of Combined MEK plus EGFR Inhibition for
Chemotherapy-Refractory Advanced Pancreatic
Adenocarcinoma
Andrew H. Ko, Tanios Bekaii-Saab, Jessica Van Ziffle,
Olga M. Mirzoeva, Nancy M. Joseph, AmirAli Talasaz,
Peter Kuhn, Margaret A. Tempero, Eric A. Collisson,
R. Kate Kelley, Alan P. Venook, Elizabeth Dito, Anna Ong,
Sharvina Ziyeh, Ryan Courtin, Regina Linetskaya,
Sanaa Tahiri, and W. Michael Korn
Liufu Deng, Hua Liang, Sherry Fu, Ralph R. Weichselbaum,
and Yang-Xin Fu
CANCER THERAPY: CLINICAL
26
PERSONALIZED MEDICINE AND IMAGING
Relationship between Complete Pathologic
Response to Neoadjuvant Chemotherapy and
Survival in Triple-Negative Breast Cancer
69
Christos Hatzis, W. Fraser Symmans, Ya Zhang,
Rebekah E. Gould, Stacy L. Moulder, Kelly K. Hunt,
Maysa Abu-Khalaf, Erin W. Hofstatter, Donald Lannin,
Anees B. Chagpar, and Lajos Pusztai
See related commentary, p. 3
Low Socioeconomic Status, Adverse Gene
Expression Profiles, and Clinical Outcomes in
Hematopoietic Stem Cell Transplant Recipients
Jennifer M. Knight, J. Douglas Rizzo, Brent R. Logan,
Tao Wang, Jesusa M.G. Arevalo, Jeffrey Ma, and
Steve W. Cole
See related commentary, p. 6
iv
Table of Contents
79
BIOLOGY OF HUMAN TUMORS
Early Changes in Circulating Tumor Cells Are
Associated with Response and Survival
Following Treatment of Metastatic
Neuroendocrine Neoplasms
146
Mohid S. Khan, Amy A. Kirkwood, Theodora Tsigani,
Helen Lowe, Robert Goldstein, John A. Hartley,
Martyn E. Caplin, and Tim Meyer
Siker Kimbung, Ida Johansson, Anna Danielsson,
Srinivas Veerla, Suzanne Egyhazi Brage,
Marianne Frostvik Stolt, Lambert Skoog, Lena Carlsson,
Zakaria Einbeigi, Elisabet Lidbrink, Barbro Linderholm,
Niklas Loman, Per-Olof Malmstr€
om, Martin S€
oderberg,
Thomas M. Walz, Marten Fern€
o, Thomas Hatschek, and
Ingrid Hedenfalk in collaboration with the TEX study
group
CANCER THERAPY: PRECLINICAL
86
Interactions between Ibrutinib and Anti-CD20
Antibodies: Competing Effects on the Outcome
of Combination Therapy
Martin Skarzynski, Carsten U. Niemann, Yuh Shan Lee,
Sabrina Martyr, Irina Maric, Dalia Salem,
Maryalice Stetler-Stevenson, Gerald E. Marti,
Katherine R. Calvo, Constance Yuan, Janet Valdez,
Susan Soto, Mohammed Z.H. Farooqui,
Sarah E.M. Herman, and Adrian Wiestner
96
158
CD73 Expression Is an Independent Prognostic
Factor in Prostate Cancer
Bruno G. Leclerc, Roxanne Charlebois,
Guillaume Chouinard, Bertrand Allard, Sandra Pommey,
Fred Saad, and John Stagg
167
Activin Receptor-like Kinase 1 Ligand Trap
Reduces Microvascular Density and Improves
Chemotherapy Efficiency to Various Solid
Tumors
Antigen Selection Shapes the T-cell Repertoire
in Chronic Lymphocytic Leukemia
Anna Vardi, Andreas Agathangelidis, Evangelia Stalika,
Maria Karypidou, Alexandra Siorenta,
Achilles Anagnostopoulos, Richard Rosenquist,
Anastasia Hadzidimitriou, Paolo Ghia, Lesley-Ann Sutton,
and Kostas Stamatopoulos
Lukas J.A.C. Hawinkels, Amaya Garcia de Vinuesa,
Madelon Paauwe, Marianna Kruithof-de Julio,
Eliza Wiercinska, Evangelia Pardali, Laura Mezzanotte,
Stijn Keereweer, Tanya M. Braumuller,
Renier C. Heijkants, Jos Jonkers, Clemens W. L€
owik,
Marie-Jose Goumans, Timo L. ten Hagen, and
Peter ten Dijke
107
Transcriptional Profiling of Breast Cancer
Metastases Identifies Liver Metastasis–Selective
Genes Associated with Adverse Outcome in
Luminal A Primary Breast Cancer
175
PKCa Attenuates Jagged-1–Mediated Notch
Signaling in ErbB-2–Positive Breast Cancer to
Reverse Trastuzumab Resistance
Kinnari Pandya, Debra Wyatt, Brian Gallagher, Deep Shah,
Andrew Baker, Jeffrey Bloodworth, Andrei Zlobin,
Antonio Pannuti, Andrew Green, Ian O. Ellis,
Aleksandra Filipovic, Jason Sagert, Ajay Rana,
Kathy S. Albain, Lucio Miele, Mitchell F. Denning, and
Clodia Osipo
Integrating Murine and Clinical Trials with
Cabozantinib to Understand Roles of MET and
VEGFR2 as Targets for Growth Inhibition of
Prostate Cancer
Andreas Varkaris, Paul G. Corn, Nila U. Parikh,
Eleni Efstathiou, Jian H. Song, Yu-Chen Lee, Ana Aparicio,
Anh G. Hoang, Sanchaika Gaur, Lynnelle Thorpe,
Sankar N. Maity, Menashe Bar Eli, Bogdan A. Czerniak,
Yiping Shao, Mian Alauddin, Sue-Hwa Lin,
Christopher J. Logothetis, and Gary E. Gallick
187
ROS-Induced CXCR4 Signaling Regulates
Mantle Cell Lymphoma (MCL) Cell Survival
and Drug Resistance in the Bone Marrow
Microenvironment via Autophagy
Zheng Chen, Albert E. Teo, and Nami McCarty
122
Coadministration of Trametinib and Palbociclib
Radiosensitizes KRAS-Mutant Non–Small Cell
Lung Cancers In Vitro and In Vivo
200
Zhen Tao, Justin M. Le Blanc, Chenguang Wang,
Tingting Zhan, Hongqing Zhuang, Ping Wang,
Zhiyong Yuan, and Bo Lu
134
Soluble Vascular Endothelial Growth Factor
(sVEGF) and the Risk of Venous
Thromboembolism in Patients with Cancer:
Results from the Vienna Cancer and Thrombosis
Study (CATS)
Florian Posch, Johannes Thaler,
Gerhard-Johann Zlabinger, Oliver K€
onigsbr€
ugge,
Silvia Koder, Christoph Zielinski, Ingrid Pabinger, and
Cihan Ay
Indole-3-Carbinol Synergizes with and Restores
Fludarabine Sensitivity in Chronic Lymphocytic
Leukemia Cells Irrespective of p53 Activity and
Treatment Resistances
Gema Perez-Chacon, Carolina Martinez-Laperche,
Nerea Rebolleda, Beatriz Somovilla-Crespo,
Cecilia Mu~
noz-Calleja, Ismael Bu~
no, and Juan M. Zapata
v
Table of Contents
207
250
Post-transcriptional Modifications Contribute
to the Upregulation of Cyclin D2 in Multiple
Myeloma
Anna Karpathakis, Harpreet Dibra,
Chistodoulos Pipinikas, Andrew Feber, Tiffany Morris,
Joshua Francis, Dahmane Oukrif, Dalvinder Mandair,
Marinos Pericleous, Mullan Mohmaduvesh,
Stefano Serra, Olagunju Ogunbiyi, Marco Novelli,
TuVinh Luong, Sylvia L. Asa, Matthew Kulke,
Christos Toumpanakis, Tim Meyer, Martyn Caplin,
Matthew Meyerson, Stephan Beck, and
Christina Thirlwell
Irena Misiewicz-Krzeminska, María E. Sarasquete,
Carolina Vicente-Due~
nas, Patryk Krzeminski,
Katarzyna Wiktorska, Luis Antonio Corchete,
Dalia Quwaider, Elizabeta A. Rojas, Rocío Corral,
Ana A. Martín, Fernando Escalante, Abelardo Barez,
Juan Luis García, Isidro Sanchez-García,
Ram
on García-Sanz, Jesús F. San Miguel, and
Norma C. Gutierrez
218
259
Prognostic and Chemotherapy Predictive Value
of Gene-Expression Phenotypes in Primary Lung
Adenocarcinoma
EphA2 Expression Is a Key Driver of Migration
and Invasion and a Poor Prognostic Marker in
Colorectal Cancer
LETTERS TO THE EDITOR
268
Philip D. Dunne, Sonali Dasgupta, Jaine K. Blayney,
Darragh G. McArt, Keara L. Redmond, Jessica-Anne Weir,
Conor A. Bradley, Takehiko Sasazuki, Senji Shirasawa,
Tingting Wang, Supriya Srivastava, Chee Wee Ong,
Ken Arthur, Manuel Salto-Tellez, Richard H. Wilson,
Patrick G. Johnston, and Sandra Van Schaeybroeck
243
The FGFR Landscape in Cancer: Analysis of 4,853
Tumors by Next-Generation Sequencing
Teresa Helsten, Sheryl Elkin, Elisa Arthur,
Brett N. Tomson, Jennifer Carter, and Razelle Kurzrock
Markus Ringner, G€
oran J€
onsson, and Johan Staaf
230
Prognostic Impact of Novel Molecular Subtypes
of Small Intestinal Neuroendocrine Tumor
Neoadjuvant as Future for Drug Development in
Breast Cancer—Letter
Marc Buyse, Tomasz Burzykowski, and Everardo D. Saad
269
Neoadjuvant as Future for Drug Development in
Breast Cancer—Response
Angela DeMichele, Douglas Yee, Melissa Paoloni,
Don Berry, and Laura J. Esserman, on behalf of the I-SPY2
Investigators
Absolute Effect of Prostate Cancer Screening:
Balance of Benefits and Harms by Center within
the European Randomized Study of Prostate
Cancer Screening
Anssi Auvinen, Sue M. Moss, Teuvo L.J. Tammela,
Kimmo Taari, Monique J. Roobol, Fritz H. Schr€
oder,
Chris H. Bangma, Sigrid Carlsson, Gunnar Aus,
Marco Zappa, Donella Puliti, Louis J. Denis, Vera Nelen,
Maciej Kwiatkowski, Marco Randazzo, Alvaro Paez,
Marcos Lujan, and Jonas Hugosson
RETRACTION
270
Retraction: Suppression of N-Methyl-Nnitrosourea/Testosterone-Induced Rat Prostate
Cancer Growth by Celecoxib: Effects on
Cyclooxygenase-2, Cell Cycle Regulation, and
Apoptosis Mechanism(s)
AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
vi
Table of Contents
ABOUT THE COVER
The cover shows a section from a patient-derived xenograft of prostate cancer grown in mice treated with
the MET/VEGFR-2 inhibitor, cabozantinib. Immunohistochemical staining shows an islet of viable
tumor cells surrounding a VEGFR-2-negative blood vessel, with apoptotic cells surrounding the islet. For
details, see the article by Varkaris and colleagues on page 107 of this issue.
vii